CD274 and neoplasm: Many preclinical studies have demonstrated that blockade of these ICs, particularly PD-1 and PD-L1, with monoclonal antibodies enhances tumor cell-specific T-cell activation, cytokine production, anti-tumor effector mechanisms, and clearance of tumor cells by the immune system2–4.